DYADIC INTERNATIONAL INC Foreign Income Tax Expense (Benefit), Continuing Operations
DYADIC INTERNATIONAL INC (DYAI) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-30.
Discontinued › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2020-03-30
- DYADIC INTERNATIONAL INC foreign income tax expense (benefit), continuing operations for fiscal 2019 was $0.00.
- DYADIC INTERNATIONAL INC foreign income tax expense (benefit), continuing operations for fiscal 2018 was $0.00.
- DYADIC INTERNATIONAL INC foreign income tax expense (benefit), continuing operations for fiscal 2017 was $0.00.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-30 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-30 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |